Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...

According to a Bloomberg report citing a Morgan Stanley note, the firm picked Microsoft, Amazon, and Meta as its favorites ...

Met a bulin, a Texas-based biotechnology company led by Hua Tu, PhD, is working to develop an ultra-stable insulin formulation that remains viable even at high temperatures. “Insulin instability has ...

A Delaware judge dismissed a former Aurion Biotech executive's challenge to a stockholder's alleged takeover of the company, ...

Venture funding and steady openings are pushing Peninsula biotech to hire — and some displaced tech workers may land in labs.

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

Vedana Therapeutics emerged from stealth with a $46M Series A. Led by local biotech veterans, the Seattle startup is developing next-gen, at-home migraine injections.